Conference Coverage
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:00:00
- Mas informaciones
Informações:
Sinopsis
Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
